Why India rejected a patent application for shorter drug-resistant TB treatment | Explained
India's patent office denied a request to patent a shortened regimen for treating drug‑resistant tuberculosis. Officials said the application did not meet criteria for novelty and inventive step. The refusal could enable more generic manufacturers to produce the therapy, potentially increasing competition. However, any reduction in treatment prices will hinge on the drug’s market availability, pricing strategies, and patients’ access to healthcare services.